• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Aerovate Therapeutics Inc.

    4/30/25 4:51:40 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)


    JADE BIOSCIENCES, INC.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    008064206

    (CUSIP Number)


    Peter Kolchinsky
    RA Capital Management, L.P., 200 Berkeley Street, 18th Floor
    Boston, MA, 02116
    617.778.2500

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    04/28/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    008064206


    1 Name of reporting person

    RA Capital Management, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,324,954.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,324,954.00
    11Aggregate amount beneficially owned by each reporting person

    1,324,954.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.1 %
    14Type of Reporting Person (See Instructions)

    IA, PN



    SCHEDULE 13D

    CUSIP No.
    008064206


    1 Name of reporting person

    Peter Kolchinsky
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,324,954.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,324,954.00
    11Aggregate amount beneficially owned by each reporting person

    1,324,954.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.1 %
    14Type of Reporting Person (See Instructions)

    HC, IN



    SCHEDULE 13D

    CUSIP No.
    008064206


    1 Name of reporting person

    Rajeev Shah
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,324,954.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,324,954.00
    11Aggregate amount beneficially owned by each reporting person

    1,324,954.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.1 %
    14Type of Reporting Person (See Instructions)

    HC, IN



    SCHEDULE 13D

    CUSIP No.
    008064206


    1 Name of reporting person

    RA Capital Healthcare Fund, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,287,858.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,287,858.00
    11Aggregate amount beneficially owned by each reporting person

    1,287,858.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.0 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.0001 par value per share
    (b)Name of Issuer:

    JADE BIOSCIENCES, INC.
    (c)Address of Issuer's Principal Executive Offices:

    930 WINTER STREET, SUITE M-500, WALTHAM, MASSACHUSETTS , 02451.
    Item 1 Comment:
    Item 1 of the Statement is amended and supplemented as follows: This Amendment No. 4 (this "Amendment No. 4" or this "13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on July 12, 2021, and amended on June 27, 2023, April 30, 2024 and June 20, 2024 (as amended, the "Statement") by the Reporting Persons. Unless otherwise defined herein, capitalized terms used in this Amendment No. 4 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.
    Item 2.Identity and Background
    (a)
    This Amendment No. 4 is being filed on behalf of RA Capital Management, L.P. ("RA Capital"), Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the "Fund"), who are collectively referred to herein as the "Reporting Persons." The agreement among the Reporting Persons to file this 13D/A jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended (the "Act"), is attached hereto as Exhibit 99.1. The Reporting Persons' ownership of the Issuer's securities includes (i) 1,287,858 shares of common stock held directly by the Fund; (ii) 28,206 shares of common stock held by RA Capital Nexus Fund, L.P. (the "Nexus Fund") and (iii) 8,890 shares of common stock held by a separately managed account (the "Account"). RA Capital Healthcare Fund GP, LLC is the general partner of the Fund and RA Capital Nexus Fund GP, LLC is the general partner of the Nexus Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund, the Nexus Fund and the Account and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act"), of any securities of the Issuer held by the Fund, the Nexus Fund or the Account. The Fund and the Nexus Fund have delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund's and the Nexus Fund's portfolio, including the shares of the Issuer's common stock reported herein. Because the Fund and the Nexus Fund have divested themselves of voting and investment power over the reported securities they hold and may not revoke that delegation on less than 61 days' notice, the Fund and the Nexus Fund disclaim beneficial ownership of the securities they hold for purposes of Section 13(d) of the Act and therefore disclaim any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13D/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13D/A shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.
    (b)
    The address of the principal business office of each of the Reporting Persons is 200 Berkeley Street, 18th Floor, Boston, MA 02116.
    (c)
    The Fund is a private investment vehicle. RA Capital provides investment management services to the Fund, the Nexus Fund and the Account. The principal occupation of Dr. Kolchinsky and Mr. Shah is investment management.
    (d)
    During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree of final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    See Item 6 of the cover pages.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Item 3 of the Statement is hereby amended and supplemented as follows: On April 28, 2025, the Issuer completed the transactions contemplated by the Agreement and Plan of Merger, dated October 30, 2024 (the "Merger Agreement"), by and among the Issuer, Caribbean Merger Sub I, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub I"), Caribbean Merger Sub II, LLC, a wholly owned subsidiary of the Issuer ("Merger Sub II" and together with Merger Sub I, "Merger Subs"), and Jade Biosciences, Inc., ("Old Jade"), pursuant to which, among other matters, Merger Sub I merged with and into Old Jade, with Old Jade surviving the merger as the surviving corporation (the "First Merger"), and as part of the same overall transaction, Old Jade merged with and into Merger Sub II, with Merger Sub II continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "Second Merger" and together with the First Merger, the "Merger"). In connection with the closing of the Merger Agreement, the Issuer changed its name to Jade Biosciences, Inc. In connection with and prior to the Closing of the Merger, on April 28, 2025, the Issuer effected a reverse split of its common stock (the "Reverse Stock Split"), pursuant to which each 35 shares of common stock issued and outstanding immediately prior to the Reverse Stock Split were automatically without further action on the part of the Issuer or any holders of such common stock, reclassified, combined, converted and changed into one share of common stock. Immediately prior to the closing of the Merger, the Fund purchased 1,683,294 shares of Old Jade common stock in a private offering (the "Old Jade Pre-Closing Financing") for an aggregate purchase price of $9,999,998.31. The purchase of these securities was for cash and was funded by working capital of the Fund. At the effective time of the First Merger, Old Jade common stock (including shares of Old Jade common stock issued in the Old Jade Pre-Closing Financing) was converted into shares of the Issuer's common stock based on an exchange ratio (after giving effect to the Reverse Stock Split) of 0.6311 shares of the Issuer's common stock for each share of Old Jade common stock. Prior to, and in connection with the closing of, the Merger, on April 28, 2025, Mr. Resnick resigned his position as a director of the Issuer. At the effective time of the Merger, each of Mr. Resnick's pre-existing options to purchase shares of common stock, which were held by Mr. Resnick for the benefit of RA Capital, were cancelled for no consideration.
    Item 5.Interest in Securities of the Issuer
    (a)
    Rows 11 and 13 of each Reporting Person's cover page to this Schedule 13D/A set forth the aggregate number of shares of common stock and percentages of the shares of common stock beneficially owned by such Reporting Person and are incorporated by reference. The percentage set forth in each row 13 is based upon 32,235,927 shares of common stock outstanding as of April 28, 2025, as reported to the Reporting Persons by the Issuer.
    (b)
    Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D/A set forth the number of shares of common stock as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.
    (c)
    Except as set forth herein, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days.
    (d)
    No person (other than the Reporting Persons) is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities subject to this Statement.
    (e)
    The Reporting Persons ceased to be the beneficial owners of more than five percent of the common stock on April 28, 2025.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 99.1 Joint Filing Agreement

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    RA Capital Management, L.P.
     
    Signature:/s/ Peter Kolchinsky
    Name/Title:By Peter Kolchinsky, Authorized Signatory
    Date:04/30/2025
     
    Peter Kolchinsky
     
    Signature:/s/ Peter Kolchinsky
    Name/Title:Peter Kolchinsky
    Date:04/30/2025
     
    Rajeev Shah
     
    Signature:/s/ Rajeev Shah
    Name/Title:Rajeev Shah
    Date:04/30/2025
     
    RA Capital Healthcare Fund, L.P.
     
    Signature:/s/ Peter Kolchinsky
    Name/Title:By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
    Date:04/30/2025
    Get the next $AVTE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVTE

    DatePrice TargetRatingAnalyst
    6/18/2024$27.00 → $2.00Outperform → In-line
    Evercore ISI
    6/18/2024Buy → Hold
    TD Cowen
    6/18/2024$35.00 → $2.00Overweight → Equal Weight
    Wells Fargo
    6/17/2024Buy → Neutral
    Guggenheim
    6/17/2024Buy → Neutral
    BTIG Research
    6/17/2024$41.00 → $3.00Outperform → Neutral
    Wedbush
    3/25/2024$21.00 → $65.00Buy
    Jefferies
    12/8/2023$35.00Equal Weight
    Wells Fargo
    More analyst ratings

    $AVTE
    Financials

    Live finance-specific insights

    See more
    • Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals

      —Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger. The proposals were voted upon at Aerovate's special meeting of stockholders held on April 16, 2025 (the "Special Meeting"), including a reverse stock split of Aerovate's common stock to be effected at the discretion of the Board of Directors (the "Board") within the parameters approved by Aerovate's stockholders. On April 18, 2025, the Board approved a fi

      4/21/25 8:00:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

      Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share WALTHAM, Mass., April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade") pursuant to the Agreement and Plan of Merger, dated October 30, 2024 (the "Merger Agreement"). The Cash Dividend will be an aggregate of $69.6 million, or an estimated $2.40 per share, payable in cash to the stockholders of record as of April 25, 2025. The estimated per share dividend is based on 28,985,019 shares of

      4/9/25 4:05:00 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

      Cash dividend expected to be in the range of $67.6 – 69.6 million WALTHAM, Mass., April 7, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), it expects to declare a cash dividend to the pre-Merger Aerovate stockholders (the "Cash Dividend") in the range of $67.6 – 69.6 million in the aggregate. This expected dividend range is based on Aerovate's estimated net cash immediately prior to the closing of the Merger (the "Closing"). As of April 4, 2025, 28,985,019 shares of Aerovate's common stock are outstanding. Official declaration of the Cash D

      4/7/25 8:30:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aerovate Therapeutics Inc.

      SC 13G/A - Aerovate Therapeutics, Inc. (0001798749) (Subject)

      11/14/24 4:21:04 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Aerovate Therapeutics Inc.

      SC 13D/A - Aerovate Therapeutics, Inc. (0001798749) (Subject)

      6/20/24 6:00:09 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aerovate Therapeutics Inc. (Amendment)

      SC 13D/A - Aerovate Therapeutics, Inc. (0001798749) (Subject)

      4/30/24 4:16:13 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Leadership Updates

    Live Leadership Updates

    See more
    • Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

      WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board. Mr. Dable succeeds Mark Iwicki, who will continue to serve on the Board. "We are pleased to have Habib take on the role of Chair of the Board," said Tim Noyes, Chief Executive Officer of Aerovate Therapeutics. "With the Phase 2b data readout from our global IMPAHCT trial of AV-101 in PAH coming in June and our Phase 3 trial already well underway,

      3/6/24 8:00:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors

      WALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Habib Dable as a member of Aerovate's Board of Directors. Mr. Dable is the former President and Chief Executive Officer of Acceleron Pharma Inc. and brings nearly three decades of experience working with emerging biotech and big pharma companies. "We are excited to welcome Habib to Aerovate's Board of Directors. Habib's deep experience in leading both big pharma and emerging biotech companies will be incredibly

      7/11/23 5:00:00 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors

      WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as a member of Aerovate's Board of Directors. With over 40 years of working in the industry, Mr. Santel brings to Aerovate extensive experience in building successful pharmaceutical companies. "We are excited to welcome Don to Aerovate's Board of Directors. Don's proven track record of leading and building biopharmaceutical companies from the ground up and taking them through extensive periods of g

      1/23/23 8:00:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $AVTE
    SEC Filings

    See more
    • Aerovate Therapeutics downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Aerovate Therapeutics from Outperform to In-line and set a new price target of $2.00 from $27.00 previously

      6/18/24 7:32:31 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics downgraded by TD Cowen

      TD Cowen downgraded Aerovate Therapeutics from Buy to Hold

      6/18/24 7:23:55 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Aerovate Therapeutics from Overweight to Equal Weight and set a new price target of $2.00 from $35.00 previously

      6/18/24 7:22:03 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Material Modification to Rights of Security Holders, Regulation FD Disclosure

      8-K - Jade Biosciences, Inc. (0001798749) (Filer)

      5/1/25 4:22:23 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Aerovate Therapeutics Inc.

      SCHEDULE 13D/A - Jade Biosciences, Inc. (0001798749) (Subject)

      4/30/25 4:51:40 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Aerovate Therapeutics, Inc. (0001798749) (Filer)

      4/29/25 4:05:20 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Fairmount Funds Management Llc

      4 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 6:16:57 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lavelle Erin

      4 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 6:15:30 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Klein Lawrence Otto

      4 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 6:10:20 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. bought $1,549,944 worth of shares (928,110 units at $1.67) (SEC Form 4)

      4 - Aerovate Therapeutics, Inc. (0001798749) (Issuer)

      6/20/24 5:56:07 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • What Led to the Purchase at Aerovate Therapeutics Inc. on Jun 20?

      Recently, on June 20, 2024, a notable insider purchase was made at Aerovate Therapeutics Inc. Director Ra Capital Management, L.P. bought $1,549,944 worth of shares, acquiring 928,110 units at $1.67 per share as reported in the SEC Form 4. Insider transactions like these are closely watched by investors as they can provide valuable insights into the company's prospects. When analyzing insider transactions, it is essential to look for patterns and trends among multiple transactions to gauge the overall sentiment within the company. Several other SEC Form 4 filings were made around the same time, on June 7, 2024, by various insiders at Aerovate Therapeutics Inc. These included transactions by

      6/21/24 3:23:59 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals

      —Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger. The proposals were voted upon at Aerovate's special meeting of stockholders held on April 16, 2025 (the "Special Meeting"), including a reverse stock split of Aerovate's common stock to be effected at the discretion of the Board of Directors (the "Board") within the parameters approved by Aerovate's stockholders. On April 18, 2025, the Board approved a fi

      4/21/25 8:00:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

      Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share WALTHAM, Mass., April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade") pursuant to the Agreement and Plan of Merger, dated October 30, 2024 (the "Merger Agreement"). The Cash Dividend will be an aggregate of $69.6 million, or an estimated $2.40 per share, payable in cash to the stockholders of record as of April 25, 2025. The estimated per share dividend is based on 28,985,019 shares of

      4/9/25 4:05:00 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

      Cash dividend expected to be in the range of $67.6 – 69.6 million WALTHAM, Mass., April 7, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), it expects to declare a cash dividend to the pre-Merger Aerovate stockholders (the "Cash Dividend") in the range of $67.6 – 69.6 million in the aggregate. This expected dividend range is based on Aerovate's estimated net cash immediately prior to the closing of the Merger (the "Closing"). As of April 4, 2025, 28,985,019 shares of Aerovate's common stock are outstanding. Official declaration of the Cash D

      4/7/25 8:30:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care